RESUMO
BACKGROUND: Highly cross-linked polyethylene (HXLPE) acetabular bearing surfaces have appeared to offer excellent wear resistance, low incidence of wear-related osteolysis, and high implant survivorship at 10-year to 15-year follow-up. However, concerns over potential performance deterioration at longer-term follow-up remain - particularly in younger patients - and outcome data into the third decade have not been available. METHODS: We retrospectively assessed 62 patients (68 hips) who underwent primary total hip arthroplasty (THA) at age ≤50 years with a single manufacturer's cementless components, remelted HXLPE liner, and small diameter (26 and 28 millimeter) cobalt-chromium (CoCr) femoral heads at minimum 18-year follow-up. We assessed clinical outcomes (modified Harris Hip score, University of California Los Angeles Activity Score, polyethylene wear rates, radiographic findings (osteolysis, component loosening), and implant survivorship. RESULTS: At 20.6-year mean follow-up (range, 18 to 23 years) modified Harris Hip scores for surviving hips remained an average of 41 points above preoperative baseline (49 versus 90, P < .001) and UCLA scores 2.8 points above baseline (3.7 versus 6.4, P < .001). Wear analysis revealed a population linear wear rate of 0.0142 mm/y (standard deviation (SD), 0.0471) and volumetric wear rate of 10.14 mm3/y (SD, 23.41). Acetabular lysis was noted in 2 asymptomatic hips at 16.6 and 18.4 years. No components were radiographically loose. Survivorship free from wear-related revision was 100% at 20 years (97% free from any revision). CONCLUSION: The HXLPE-CoCr bearing couple with small femoral heads continues to be extremely effective 20 years after primary THA in the younger patient population.
Assuntos
Artroplastia de Quadril , Prótese de Quadril , Osteólise , Humanos , Pessoa de Meia-Idade , Artroplastia de Quadril/efeitos adversos , Polietileno , Prótese de Quadril/efeitos adversos , Estudos Retrospectivos , Cromo , Cobalto , Cabeça do Fêmur/cirurgia , Osteólise/etiologia , Falha de Prótese , Desenho de Prótese , SeguimentosRESUMO
BACKGROUND: Conventional polyethylene (CPE) was used widely in the past as a bearing surface in total hip arthroplasty (THA). As CPE THAs age and the revision burden continues to grow, it is increasingly important to understand the durability and failure mechanisms of this bearing material. Currently, such long-term data remain limited, particularly in younger, more active patients in whom wear issues are of greater concern. METHODS: We retrospectively reviewed 90 hips (77 patients) that underwent primary THA with CPE bearings on cobalt chrome femoral heads at age ≤50 years at 20-year minimum follow-up (mean 21.6 [20-23]). We analyzed polyethylene wear rates, clinical outcomes (modified Harris Hip Score, University of California, Los Angeles Activity Score), and implant survivorship. RESULTS: Wear analysis revealed a median linear wear rate of 0.113 mm/y (95% CI 0.102-0.148) and a median volumetric wear rate of 41.20 mm3/y (95% CI 43.5-61.0). Modified Harris Hip Scores remained 37 points above preoperative baseline (P < .001) and University of California, Los Angeles scores 1.4 points above baseline (P = .018) at 21.6-year mean follow-up. Twenty-nine hips (32.2%) were revised, 20 of which (22.2%) were wear-related at a median of 15.4 years (interquartile range 11.4-19.5). Survivorship free from wear-related revision was 95.6% (95% CI 88.7-98.3), 87.9% (78.6-93.3), 78.1% (49.6-66.5), and 61.1% (41.3-67.0) at 10, 15, 20, and 25 years. CONCLUSION: Wear-related issues developed at increasingly high rates after 15 years, suggesting the need for surveillance after this time. The long-term wear and survivorship data of this study may be used as a benchmark when evaluating the performance of contemporary bearings in young, active THA patients.
Assuntos
Artroplastia de Quadril , Prótese de Quadril , Artroplastia de Quadril/efeitos adversos , Seguimentos , Prótese de Quadril/efeitos adversos , Humanos , Pessoa de Meia-Idade , Polietileno , Desenho de Prótese , Falha de Prótese , Estudos RetrospectivosRESUMO
BACKGROUND: Although femoral osteoplasty is common practice in treating cam-type femoroacetabular impingement (FAI), long-term data are lacking that support the ability of this procedure to optimize outcomes and alter natural history. PURPOSE: To compare long-term clinical outcomes and survivorship of treatment for symptomatic FAI via arthroscopic correction of labral or chondral pathology with and without femoral osteoplasty. STUDY DESIGN: Cohort study; Level of evidence, 3. METHODS: A retrospective cohort study was performed across 2 consecutive cohorts of patients with isolated cam-type FAI who underwent hip arthroscopic treatment of labral or chondral pathology without femoral osteoplasty (HS group) or with femoral osteoplasty (HS-OST group). These unique cohorts were established at a distinct transition time in our practice before and after adoption of femoral osteoplasty for treatment of FAI. Clinical outcomes were measured using the modified Harris Hip Score (mHHS). Kaplan-Meier analysis was used to assess for total hip arthroplasty (THA)-free and reoperation-free survivorship. RESULTS: The final HS group included 17 hips followed for 19.7 ± 1.2 years, and the final HS-OST group included 23 hips followed for 16.0 ± 0.6 years. No significant patient or morphological differences were found between groups. Compared with the HS group, the HS-OST group had significantly higher final mHHS (82.7 vs 64.7 for HS-OST vs HS, respectively; P = .002) and mHHS improvement (18.4 vs 6.1; P = .02). The HS-OST group also had significantly greater 15-year THA-free survivorship versus the HS group (78% vs 41%, respectively; P = .02) and reoperation-free survivorship (78% vs 29%; P = .003). CONCLUSION: This study demonstrated superior long-term clinical outcomes and survivorship with combined arthroscopy and femoral osteoplasty compared with hip arthroscopy alone. These long-term data strongly support the practice of femoral osteoplasty in patients with cam FAI morphologies and suggest that this treatment alters the natural history of FAI at long-term follow-up.